Top videos
Source ABC7, 24 November 2009 An initial single-arm Phase II trial (ACT II) has reported promising preliminary data in 23 patients who received CDX-110 vaccine. Median time to disease progression was 16.6 months and estimated median overall survival was 33.1 months. This compared favorably with data for a historical control group in which median time to progression was 6.4 months and median overall survival was 15.2 months. The study was sponsored by Celldex Therapeutics Inc. of Phillipsburg, NJ
Chapel Hill Tubal Reversal Center - www.tubal-reversal.net - illustrates proper hand hygiene technique for surgical scrub to disinfect the hands prior to entering the operating room for tubal ligation reversal surgery.
The 3rd Annual W. B. Ingalls Memorial
Prostate Health and Cancer Seminar features nationally renowned physicians and scientists presenting the most current study and practices for the diagnosis and treatment of prostate cancer. This day-long program offers in-depth exploration of prostate issues that range from monitoring PSA counts to cutting-edge research to current treatment trends.
Operation ofInguinal hernia repair without mesh, Desarda Repair, no recurrence, pain, no mesh hernia surgery, hernia operation, no mesh, without mesh, hernia operation, hernia surgery, new method.